Yeseul Kim

Yeseul Kim

Auto-generated profile, based on publicly available information

Yeseul Kim

Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
YKYeseul Kim
Yeseul Kim
GKGayoung Kim
Gayoung Kim
HSHyun-June Shin
Hyun-June Shin
JHJae-Won Hyun
Jae-Won Hyun
SKSu-Hyun Kim
Su-Hyun Kim
HKHo Jin Kim
Ho Jin Kim
Regulatory B cells (Bregs), which protect from autoimmunity, are deficient in multiple sclerosis (MS). Novel regulatory B cell subsets CD19+CD24hiCD38hi cells and CD19+PD-L1hi cells, with disparate regulatory mechanisms have been defined. Alemtuzumab provides a long-lasting suppression of disease activity in MS. In contrast to its documented efficacy, alemtuzumab’s mechanism of action is not fully understood and information about the composition of repopulating B cell pool is scarce. To characterize repopulated B cell subsets and elucidate alemtuzumab’s mechanism of action in B cell perspective. The frequency and the absolute number of Bregs were studied in peripheral blood mononuclear cells (PBMC) of 37 MS patients and 11 healthy controls (HC). Longitudinal analysis of the frequency and the absolute number of Bregs in PBMC of 11 MS patients was evaluated, before and at 6, 9, and 12 months post alemtuzumab. We found deficiency of CD19+CD24hiCD38hi cells during relapse compared to remission and HC (relapse vs remission: p = 0.0006, relapse vs HC: p = 0.0004). CD19+PD-L1hi cells were deficient during relapse than remission and HC (relapse vs remission: p = 0.0113, relapse vs HC: p = 0.0007). Following alemtuzumab, the distribution of B cells shifts towards naïve phenotype and Breg deficiency is restored. The frequency of CD19+CD24hiCD38hi cells was significantly increased at 6 M and 9 M compared to 0 M (6 M vs 0 M: p = 0.0004, 9 M vs 0 M: p = 0.0079). At 9 M, the frequency of CD19+CD24hiCD38hi cells started to decrease and by 12 M the frequency was reduced compared to 6 M, although it was significantly higher than baseline level (12 M vs 0 M: p = 0.0257). The absolute number was significantly increased at 6 M and 9 M post-alemtuzumab (6 M vs 0 M: p = 0.0063, 9 M vs 0 M: p = 0.02). The frequency of CD19+PD-L1hi cells significantly increased until 12 M (6 M vs 0 M: p = 0.0004, 12 M vs 0 M: p = 0.0036). The frequency of CD19+PD-L1hi cells at 12 M was significantly higher than 9 M (p = 0.0311). We further pinpoint that CD19+CD24hiCD38hi cells were deficient at severe relapses following alemtuzumab infusion and restored during recovery. Our results highlight the preferential reconstitution of Bregs as a possible mechanism of action of alemtuzumab and CD19+CD24hiCD38hi cells as a potential biomarker for disease activity.

1 January 2017 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
YKYeseul Kim
Yeseul Kim
GKGayoung Kim
Gayoung Kim
BKByung Soo Kong
Byung Soo Kong
JLJi-Eun Lee
Ji-Eun Lee
YOYu-Mi Oh
Yu-Mi Oh
HKHo Jin Kim
Ho Jin Kim
Kim Y, et al. J Clin Neurol. 2017 Apr;13(2):175-180. https://doi.org/10.3988/jcn.2017.13.2.175

1 May 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
JHJae-Won Hyun
Jae-Won Hyun
YKYeseul Kim
Yeseul Kim
SKSo Yeon Kim
So Yeon Kim
MLMin Young Lee
Min Young Lee
SKSu-Hyun Kim
Su-Hyun Kim
HKHo Jin Kim
Ho Jin Kim
Objectives Information on subclinical astrocyte damage can provide further insight into neuromyelitis optica spectrum disorder (NMOSD) pathophysiology and disease-monitoring strategies. To investigate whether astrocyte and neuroaxonal damage occurs during interattack periods in individuals with NMOSD through longitudinal measurement of serum glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL) at multiple time points. Methods sGFAP and sNfL levels were measured in 187 serum samples from 20 participants with NMOSD treated with rituximab (median follow-up: 24 months) and 19 age-/sex-matched healthy controls using a highly sensitive single-molecule array assay. From the NMOSD cohort of National Cancer Center, Korea, 14 clinically stable participants were randomly selected for focused investigation of interattack periods, and 6 participants with clinical attacks despite treatment were enrolled for attack-related measurements. Results Significant elevations of sGFAP levels were observed in all clinical attacks, and 95% (19/20) of patients showed reduction of sGFAP levels below the cutoff value (3 SDs above mean levels in age-/sex-matched healthy controls) within 3 months of their clinical attacks. The sGFAP levels were consistently low during interattack periods in 90% (17/19) of patients whose sGFAP levels returned to below the cutoff value. Changes in sNfL levels were similar to but slower than those in sGFAP levels. Conclusions Subclinical astrocyte damage represented by increasing sGFAP levels rarely occurred during interattack periods in individuals with NMOSD; however, a certain degree of astrocyte damage did occur at the time of clinical attacks without exception, but it was not evident within 3 months of the attack.

15 December 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
YKYeseul Kim
Yeseul Kim
SKSo Yeon Kim
So Yeon Kim
SHSang-Min Han
Sang-Min Han
RPRosah May Payumo
Rosah May Payumo
KPKevin Park
Kevin Park
HKHo Jin Kim
Ho Jin Kim
Defective regulatory B cells that contribute to autoimmunity are recovered by B cell depletion therapy in patients with NMOSD.

1 January 2019 in Journal of Clinical Neurology
Verified
Journal Article
Open access
SKSu-Hyun Kim
Su-Hyun Kim
YKYeseul Kim
Yeseul Kim
JJJi Yun Jung
Ji Yun Jung
NPNa-Young Park
Na-Young Park
HJHyunmin Jang
Hyunmin Jang
HKHo Jin Kim
Ho Jin Kim
Background and Purpose The anti-John-Cunningham virus (JCV)-antibody serostatus and index are used in the risk stratification of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with natalizumab. However, little information on these parameters is available for Asian countries. The purpose of this study was to determine the rate of seropositivity, index, and longitudinal index evolution in Korean patients with MS. Methods The antibody seroprevalence was analyzed in 355 samples from 187 patients with clinically isolated syndrome or MS using a second-generation, two-step, enzyme-linked immunosorbent assay. A 4-year longitudinal evaluation was applied to 66 patients. Results The overall antibody seroprevalence was 80% (n=149). Among antibody-positive patients, the index had a median value of 3.27 (interquartile range, 1.52-4.18), with 77% (n=114) and 56% (n=83) of patients having indices >1.5 and >3.0, respectively. The serostatus of 59 (89%) of the 66 patients did not change during the longitudinal analysis, while 3 (6%) of the 53 patients who were initially seropositive reverted to seronegativity, and 2 (15%) of the 13 patients who were initially seronegative converted to seropositivity. All patients with a baseline index >0.9 maintained seropositivity, and 92% of patients with a baseline index >1.5 maintained this index over 4 years. No patients developed PML (median disease duration, 8 years). Conclusions The seroprevalence and index of anti-JCV antibodies in Korean patients with MS may be higher than those in Western countries.

6 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SKSu-Hyun Kim
Su-Hyun Kim
HGHo-Shin Gwak
Ho-Shin Gwak
YLYoungjoo Lee
Youngjoo Lee
NPNa-Young Park
Na-Young Park
MHMira Han
Mira Han
HKHo Jin Kim
Ho Jin Kim
We evaluated the potential serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) roles in diagnosing and monitoring brain metastases (BMs). We included 70 patients with newly diagnosed BMs, 71 age- and cancer type-matched patients without BMs, and 67 healthy controls (HCs). We compared sNfL and sGFAP levels among the groups using a single-molecule array immunoassay. We prospectively followed 26 patients with BMs every 2–3 months by measuring sNfL and sGFAP levels and performing magnetic resonance imaging (MRI) scans. The sNfL and the sGFAP levels were higher in patients with BMs (medians: sNfL, 63.7 mL; sGFAP, 819.5 pg/mL) than in those without BMs (sNfL, 13.3 mL; sGFAP, 154 pg/mL; p < 0.001) and HCs (sNfL, 12.5 mL; sGFAP, 135 pg/mL; p < 0.001). The sNfL and the sGFAP cutoff levels had a sensitivity and a specificity of 91%. The sGFAP cutoff level had a sensitivity of 91% and a specificity of 97%. The sNfL and the sGFAP levels were related to the BM size but not to the primary cancer type. After BM treatment, sNfL and sGFAP levels decreased with reduced BM lesions on MRI; however, they increased when BMs progressed. sNfL and sGFAP are potential biomarkers for BM screening in cancer patients.